Product NewsDrug discovery > Lead Discovery FDA Grants Priority Review Status to TopoTarget’s Application for Approval of Totect™ (Savene™)
Product NewsLife Sciences TopoTarget Announces New Preclinical Results with Belinostat to be presented at AACR Annual Meeting
Product NewsDrug discovery > Lead Discovery TopoTarget’s new antidote for accidental tissue exposure during chemotherapy, Savene™, becomes 'gold standard'
Product NewsDrug discovery > Clinical Development TopoTarget and CuraGen Initiate NCI-sponsored Phase II Clinical Trial of PXD101 for Acute Myelogenous Leukemia
Product NewsDrug discovery > Lead Discovery EMEA, the European Medicines Agency, recommends that the EU Commission should grant TopoTarget European marketing authorisation for Savene™
Product NewsDrug discovery > Lead Discovery TopoTarget reports promising Phase II trial results with Avugane™ in acne vulgaris
Product NewsDrug discovery > Lead Discovery TopoTarget and CuraGen present encouraging new preclinical data on PXD101 at the AACR 97th Annual Meeting
Product NewsDrug discovery > Lead Discovery TopoTarget and CuraGen announce initiation of first NCI-sponsored clinical trial with PXD101
Product NewsDrug discovery > Lead Discovery TopoTarget initiates pivotal Phase II trial with Savicol™ for FAP (an inherited pre-disposition to develop colon cancer)
Product NewsDrug discovery > Clinical Development TopoTarget and CuraGen initiate Phase II Trial with PXD101 for T-Cell Lymphomas (TCLs)
